1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Guidance Offers IDE Tips For Devices Targeting Brain Disease Progression

FDA issued a draft guidance to help device-makers conduct clinical trials for products designed to slow the progress of neurological conditions. One challenge highlighted by the agency is that changes to biomarkers measured in a study may not line up easily with disease progression.

Clinical trials of devices designed to slow the progression of neurological conditions such as Alzheimer’s disease shouldn’t conflate symptom improvement with biomarker changes, FDA underscores in a March 7 draft guidance.

The draft addresses investigational device exemption clinical considerations for devices targeting the cause or progression, rather than the symptoms, of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls

 
• By Brian Bossetta

Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.

Delfi Diagnostics Fragmentomics Lung Cancer Test Nears Key Milestone For FDA Path, Reimbursement

 
• By Marion Webb

Delfi Diagnostics is preparing for pivotal trial results that could support FDA approval and reimbursement for its fragmentomics-based lung cancer screening test. Early data suggest strong potential to improve screening uptake and expand access to early detection.

More from R&D

Neuromodulation Tech Raises Billions Despite Commercial Uncertainty

 
• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

Could Oura Take A Bite Out Of Apple? Company Seeks FDA Clearance For Blood Pressure Feature

 
• By Brian Bossetta

Wearables innovator Oura has launched a profile study aimed at helping the company secure FDA clearance for a blood pressure feature for its smart ring. Study participants will answer questions while wearing the ring, which the company plans to use to support the feature’s efficacy.

Brain Cancer Treatment From GT Medical Could Redefine Standard Of Care

 
• By Brian Bossetta

GT Medical says interim results from a clinical trial studying an innovative surgical procedure to treat brain tumors show promise for patients with newly diagnosed operable brain metastases.